Press releases
- GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
- DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
- FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
Tweets from GSK US
-
GSKUS @GSKUS
We’re proud to share the data results from the DREAMM study program in #multiplemyeloma at #ASCO20. Learn more: gsk.to/3cd5PU0
about 2 hours ago -
GSKUS @GSKUS
We’re working with our partner Vir Biotechnology to identify and accelerate potential antibody therapies to fight the virus that causes #COVID19. Learn more: gsk.to/2TTePqO
about 4 hours ago -
GSKUS @GSKUS
Our R&D Pres Hal Barron sat down with @Vir_Biotech’s George Scangos and @BioCentury’s @FishburnSimone to talk about our Vir + GSK collaboration and how we’re accelerating development of two antibody candidates to fight #COVID19. 🔉 Podcast here:gsk.to/3cjn2edz
about 5 hours ago
k
